Production (Stage)
Harvard Bioscience, Inc.
HBIO
$0.2843
-$0.089-23.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.40M | 94.14M | 97.73M | 101.13M | 106.79M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.40M | 94.14M | 97.73M | 101.13M | 106.79M |
| Cost of Revenue | 39.18M | 39.33M | 40.33M | 41.76M | 43.97M |
| Gross Profit | 52.22M | 54.81M | 57.40M | 59.36M | 62.82M |
| SG&A Expenses | 41.81M | 43.52M | 44.73M | 45.71M | 46.16M |
| Depreciation & Amortization | 5.08M | 5.26M | 5.39M | 5.41M | 5.47M |
| Other Operating Expenses | 24.00K | 819.00K | 819.00K | 819.00K | 966.00K |
| Total Operating Expenses | 95.93M | 99.32M | 102.50M | 105.13M | 108.32M |
| Operating Income | -4.53M | -5.19M | -4.76M | -4.00M | -1.53M |
| Income Before Tax | -57.98M | -11.67M | -13.36M | -9.43M | -8.25M |
| Income Tax Expenses | 76.00K | 740.00K | 883.00K | 1.25M | 484.00K |
| Earnings from Continuing Operations | -58.05 | -12.41 | -14.24 | -10.68 | -8.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.05M | -12.41M | -14.24M | -10.68M | -8.73M |
| EBIT | -4.53M | -5.19M | -4.76M | -4.00M | -1.53M |
| EBITDA | 2.50M | 1.97M | 2.41M | 3.14M | 5.53M |
| EPS Basic | -1.32 | -0.29 | -0.33 | -0.25 | -0.20 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.14 | -0.09 | -0.08 |
| EPS Diluted | -1.32 | -0.29 | -0.33 | -0.25 | -0.21 |
| Normalized Diluted EPS | -0.11 | -0.11 | -0.14 | -0.09 | -0.08 |
| Average Basic Shares Outstanding | 174.86M | 174.16M | 173.21M | 172.29M | 171.15M |
| Average Diluted Shares Outstanding | 175.65M | 174.96M | 173.21M | 172.29M | 171.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |